Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the ‘EVIDENCE’ study
Initial strategy was aligned with contemporary at that time European guidelines, setting a benchmark for understanding the future uptake of new therapies.
Authors
- Andriani Charpidou (ORCID: https://orcid.org/0000-0002-5107-6430)
- Helena Linardou (ORCID: https://orcid.org/0000-0002-2906-6607)
- Christina Papista
- Alvertos Somarakis
- Zoe Paparepa
- Dionysis Spyratos
- Sofia Lampaki
- Giannis Mountzios (ORCID: https://orcid.org/0000-0002-7780-7836)
- Stavros Anevlavis
- Foteini Papageorgiou
- Alexandros Glentis (ORCID: https://orcid.org/0000-0002-4055-3713)
- Nikolaos Syrigos (ORCID: https://orcid.org/0000-0001-8082-594X)
- Evangelos Sarris
- Aristeidis Nikolaou
- Maria Lykka
- Vassilis Georgoulias
- Dimitrios Mavroudis
Institutions
- National and Kapodistrian University of Athens (GR)
- Aristotle University of Thessaloniki (GR)
- AstraZeneca (Brazil) (BR)
- Athens Medical Center (GR)
- University Hospital of Heraklion (GR)
- Metropolitan Hospital (GR)
- Henry Dunant Hospital (GR)
- G. Papanikolaou General Hospital (GR)
- University Hospital of Alexandroupolis (GR)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1080/14796694.2024.2442295
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca